GSK has signed a deal with China’s largest vaccine company by revenue Zhifei, as the British drugmaker aims to double global sales of its shingles vaccine by 2026.
The UK-based pharmaceutical company said Zhifei had agreed to buy £2.5bn worth of GSK’s bestselling shot Shingrix, which is targeted at older adults, over three years.
The deal includes an option for Zhifei to also distribute GSK’s vaccine for respiratory syncytial virus (RSV) if it is approved by regulators in China.
您已阅读77%（481字），剩余23%（141字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。